For instance, Davar et al, describe 1-year, 2-year and 3-year survivals of 41%, 20% and 14%, respectively, in a large single-institution study comprising 243 patients with advanced melanoma.26 After progression on IL-2, 36 patients were treated with T-cell checkpoint antibodies and 7 (19%) have ongoing response to immunotherapy. This evidence concerns the gene IL2 and melanoma.